Pharmacoeconomic aspect of moderate and severe psoriasis treatment with biological therapy versus conventional therapy

doctoral thesis

• Author: Ante Orbanić
• Mentor: Mirna Šitum (mentor)
• Mentor: Stjepan Orešković (komentor)
• Committee member: Branka Marinović (predsjednik povjerenstva)
• Committee member: Mirjana Kujundžić Tiljak (član povjerenstva)
• Committee member: Jelena Filipović-Grčić (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Dermatology); Zagreb
• Defense date and country: 2024-09-02, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Dermatovenerology
• Universal decimal classification (UDC): 616 - Pathology. Clinical medicine

Abstract

Psoriasis is a chronic, recurrent, autoimmune skin disease. In Croatia, around 80,000 people have some form of psoriasis, and 20% have moderate or severe psoriasis. The total costs of psoriasis for patients worldwide are $11.25 billion annually.
This study aimed to show that using ustekinumab shows non-inferiority compared to acitretin and to evaluate the direct cost of treatment of moderate and severe psoriasis with different treatments.
A Retrospective study included data from 25 patients using ustekinumab and 43 patients using acitretin. Data was collected by analyzing patients' medical records.
Overall results for HRQoL and QALY were more favourable for ustekinumab 45 mg, with an HRQoL score of 0.9. The highest calculated QALY for ustekinumab 45 mg was 24.3, costing €1942.15 per QALY. Ustekinumab 45 mg showed more favourable results in terms of ICER of €-1124.25, €3721.7, and €2953.6 for PASI scores at baseline, after 12 weeks, and after 52 weeks of treatment, respectively.
This research provides insight into the complex pharmacoeconomic aspects of treating moderate and severe psoriasis, highlighting the importance of a comprehensive approach to evaluating the costs and benefits of different therapeutic approaches.

Abstract (croatian)

Psorijaza je kronična, rekurentna, autoimuna bolest kože. Procjenjuje se da u Hrvatskoj oko 80 000 ljudi ima neki oblik psorijaze, a 20% pacijenata ima srednje tešku ili tešku psorijazu. Ukupni troškovi zdravstvene zaštite oboljelih od psorijaze u svijetu procjenjuju se na 11,25 milijardi dolara godišnje.
Ciljevi ove studije bili su pokazati da primjena ustekinumaba nije inferiorna u usporedbi s acitretinom te procijeniti izravne troškove liječenja srednje teške i teške psorijaze ustekinumabom u usporedbi s acitretinom.
Provedena je retrospektivna studija koja uključuje podatke 25 pacijenata koji su primjenjivali ustekinumab i 43 pacijenata koji su primjenjivali acitretin. Podaci su prikupljeni analizom medicinske dokumentacije pacijenata.
Ukupni rezultati za HRQoL i QALY bili su povoljniji za ustekinumab 45 mg, s rezultatom HRQoL od 0,9. Najviši izračunati QALY za ustekinumab 45 mg bio je 24,3, s cijenom od 1942,15 € po QALY-u. Ustekinumab 45 mg pokazao se povoljnijim u smislu ICER-a od -1124,25 €, 3721,7 € i 2953,6 € za PASI na početku, nakon 12 tjedana odnosno nakon 52 tjedna liječenja.
Ovo istraživanje pruža uvid u složene farmakoekonomske aspekte liječenja srednje teške i teške psorijaze, ističući važnost cjelovitog pristupa procjeni troškova i uporabi različitih terapijskih pristupa.

• Keywords: Ustekinumab; Acitretin; Croatia; Psoriasis; Skin Diseases; Medical Records
• Keywords (croatian): Ustekinumab; Acitretin; Hrvatska; Psorijaza; Kožne bolesti; Medicinska dokumentacija
• Language: english
• URN:NBN: urn:nbn:hr:105:766317
• Study programme: Title: Biomedicine and Health Sciences; Study programme type: university; Study level: postgraduate; Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstvo (doktor/doktorica znanosti, područje biomedicine i zdravstvo)
• Type of resource: Text
• Extent: 75 str.
• File origin: Born digital
• Access conditions: Open access
• Created on: 2024-10-01 08:11:24